A trial looking at saracatinib for post menopausal women with advanced breast cancer (ARISTACAT)
Cancer type:
Status:
Phase:
This trial looked at the combination of saracatinib with hormone therapy, for women with advanced breast cancer who had been through the menopause.
More about this trial
- if the combination of saracatinib and an aromatase inhibitor works better than an aromatase inhibitor alone
- about the side effects
Summary of results
- 69 had an aromatase inhibitor and saracatinib tablets (group A)
- 71 had an aromatase inhibitor and dummy (placebo) tablets (group B)
- 3.7 months for those in group A
- 5.6 months for those in group B
- 30 out of 69 women (43%) in group A
- 30 out of 71 women (42%) in group B
- 24 months for those in group A
- 23 months for those in group B
- 5 out of 44 women (11%) who had an aromatase inhibitor and saracatinib (group A)
- 18 out of 59 women (31%) who had an aromatase inhibitor and the placebo (group B)
- extreme tiredness
- feeling or being sick
- infection

Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor David Cameron
Supported by
AstraZeneca
Cancer Research UK
Common Services Agency
Experimental Cancer Medicine Centre (ECMC)
ISD Cancer Clinical Trials Team
NIHR Clinical Research Network: Cancer
Other information
This is Cancer Research UK trial number CRUKE/11/023.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040